Nebu Koshy is an Oncology physician. OpenAlex indexes 74 publications with 345 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3410 Worth St Ste 300
Dallas, TX 752462012
Telephone
214-370-1500Registry record last updated 29 Jul 2019.
Industry payments
38 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Astellas Pharma US IncProgram year20255 payments
- ABBVIE INC.Program year20252 payments
- Incyte CorporationProgram year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
78.3%Human Immunoglobulin G66.8%Immune globulin100%Part B, office-administered≥13 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor4.4%Valacyclovir100%Part D≥19 patients+ 5 more classes in this area
Metabolism & gastrointestinal
6%Serotonin-3 Receptor Antagonist2.2%Ondansetron Odt62%Ondansetron Hcl38%Part D≥20 patientsProton pump inhibitor1.2%Pantoprazole Sodium100%Part D<11 patients+ 3 more classes in this area
Nervous system
3.8%SSRI1.8%Trazodone Hcl62%Escitalopram Oxalate38%Part D<11 patientsPhenothiazine0.7%Prochlorperazine Maleate100%Part D≥12 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- 131I-Apamistamab Improves Outcomes in Patients 65 Years and Older with Relapsed or Refractory AML
Biology of Blood and Marrow Transplantation
2024 - 131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R AML Results in Significantly Improved Outcomes
Biology of Blood and Marrow Transplantation
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”